Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab tirumotecan + tislelizumab
- Development stage
- Unknown
- Lead developer
- Kelun-Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab tirumotecan + tislelizumab is an investigational combination therapy being evaluated for the treatment of advanced esophageal squamous cell carcinoma (ESCC). Sacituzumab tirumotecan (also known as SKB264 or MK-2870) is a trophoblast cell-surface antigen 2 (TROP-2)-directed antibody-drug conjugate (ADC) that utilizes a humanized monoclonal antibody to deliver a cytotoxic topoisomerase I inhibitor payload (KL610023) directly to tumor cells. Tislelizumab is a humanized IgG4 monoclonal antibody designed to bind to the programmed cell death protein 1 (PD-1) receptor, thereby blocking the PD-1/PD-L1 pathway and restoring anti-tumor T-cell activity. This combination is currently being studied in a Phase II clinical trial sponsored by The First Affiliated Hospital of Zhengzhou University to assess its efficacy and safety in patients with unresectable, locally advanced, recurrent, or metastatic ESCC.
- Other names
- SKB264 + tislelizumabMK-2870 + tislelizumabSKB264 + BGB-A317
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sacituzumab tirumotecan + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab tirumotecan + tislelizumab.